These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31477779)

  • 1. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study).
    Solis-Hernandez MP; Fernandez Del Valle A; Carmona-Bayonas A; Garcia-Carbonero R; Custodio A; Benavent M; Alonso Gordoa T; Nuñez-Valdovino B; Sanchez Canovas M; Matos I; Alonso V; Lopez C; Viudez A; Izquierdo M; Calvo-Temprano D; Grande E; Capdevila J; Jimenez-Fonseca P
    Br J Cancer; 2019 Oct; 121(7):537-544. PubMed ID: 31477779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours.
    Raymond E; Kulke MH; Qin S; Yu X; Schenker M; Cubillo A; Lou W; Tomasek J; Thiis-Evensen E; Xu JM; Croitoru AE; Khasraw M; Sedlackova E; Borbath I; Ruff P; Oberstein PE; Ito T; Jia L; Hammel P; Shen L; Shrikhande SV; Shen Y; Sufliarsky J; Khan GN; Morizane C; Galdy S; Khosravan R; Fernandez KC; Rosbrook B; Fazio N
    Neuroendocrinology; 2018; 107(3):237-245. PubMed ID: 29991024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?
    Luo Y; Chen J; Huang K; Lin Y; Chen M; Xu L; Li ZP; Feng ST
    BMC Cancer; 2017 Feb; 17(1):154. PubMed ID: 28231773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revised Choi imaging criteria correlate with clinical outcomes in patients with metastatic renal cell carcinoma treated with sunitinib.
    Thian Y; Gutzeit A; Koh DM; Fisher R; Lote H; Larkin J; Sohaib A
    Radiology; 2014 Nov; 273(2):452-61. PubMed ID: 24869795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib.
    Shinagare AB; Jagannathan JP; Kurra V; Urban T; Manola J; Choy E; Demetri GD; George S; Ramaiya NH
    Eur J Cancer; 2014 Mar; 50(5):981-6. PubMed ID: 24388774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients' Outcome in Neuroendocrine Tumors (NET)-The GREPONET Study.
    Lamarca A; Crona J; Ronot M; Opalinska M; Lopez Lopez C; Pezzutti D; Najran P; Carvhalo L; Franca Bezerra RO; Borg P; Vietti Violi N; Vidal Trueba H; de Mestier L; Schaefer N; Sundin A; Costa F; Pavel M; Dromain C;
    Oncologist; 2019 Nov; 24(11):e1082-e1090. PubMed ID: 30910869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response.
    Lamarca A; Barriuso J; Kulke M; Borbath I; Lenz HJ; Raoul JL; Meropol NJ; Lombard-Bohas C; Posey J; Faivre S; Raymond E; Valle JW
    Br J Cancer; 2018 Jan; 118(2):181-188. PubMed ID: 29161241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of sunitinib in Japanese patients with progressive, advanced/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a Phase II study.
    Ito T; Tori M; Hashigaki S; Kimura N; Sato K; Ohki E; Sawaki A; Okusaka T
    Jpn J Clin Oncol; 2019 Apr; 49(4):354-360. PubMed ID: 30834940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative effectiveness of sunitinib versus everolimus in advanced pancreatic neuroendocrine tumors: an updated matching-adjusted indirect comparison.
    Ishak KJ; Rael M; Hicks M; Mittal S; Eatock M; Valle JW
    J Comp Eff Res; 2018 Oct; 7(10):947-958. PubMed ID: 30168349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms.
    Mizuno Y; Kudo A; Akashi T; Akahoshi K; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Tanaka S; Tateishi U; Tanabe M
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1155-1163. PubMed ID: 29602973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of RECIST and Choi criteria for computed tomographic response evaluation in patients with advanced gastrointestinal stromal tumor treated with sunitinib.
    Dudeck O; Zeile M; Reichardt P; Pink D
    Ann Oncol; 2011 Aug; 22(8):1828-33. PubMed ID: 21289369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.
    van der Veldt AA; Meijerink MR; van den Eertwegh AJ; Haanen JB; Boven E
    Br J Cancer; 2010 Mar; 102(5):803-9. PubMed ID: 20145618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of performance of various tumor response criteria in assessment of sunitinib activity in advanced gastrointestinal stromal tumors.
    Shinagare AB; Barysauskas CM; Braschi-Amirfarzan M; O'Neill AC; Catalano PJ; George S; Ramaiya NH
    Clin Imaging; 2016; 40(5):880-4. PubMed ID: 27179958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CT features combined with RECIST 1.1 criteria improve progression assessments of sunitinib-treated gastrointestinal stromal tumors.
    Li J; Huang S; Zhu H; Shou C; Lin T; Yin X; Zhu Q; Sun D; Li X; Shen L; Li J; Kou Y; Zhou Y; Zhang B; Qian H; Yu J; Zhou Y; Tang L; Zhang X
    Eur Radiol; 2024 Jun; 34(6):3659-3670. PubMed ID: 37947835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
    Raymond E; Dahan L; Raoul JL; Bang YJ; Borbath I; Lombard-Bohas C; Valle J; Metrakos P; Smith D; Vinik A; Chen JS; Hörsch D; Hammel P; Wiedenmann B; Van Cutsem E; Patyna S; Lu DR; Blanckmeister C; Chao R; Ruszniewski P
    N Engl J Med; 2011 Feb; 364(6):501-13. PubMed ID: 21306237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adapted Choi response criteria for prediction of clinical outcome in locally advanced gastric cancer patients following preoperative chemotherapy.
    Liu K; Li G; Fan C; Zhou C; Li J
    Acta Radiol; 2012 Mar; 53(2):127-34. PubMed ID: 22156007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.
    Gavanier M; Ayav A; Sellal C; Orry X; Claudon M; Bronowicki JP; Laurent V
    Eur J Radiol; 2016 Jan; 85(1):103-112. PubMed ID: 26724654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis.
    Taieb S; Saada-Bouzid E; Tresch E; Ryckewaert T; Bompas E; Italiano A; Guillemet C; Peugniez C; Piperno-Neumann S; Thyss A; Maynou C; Clisant S; Penel N;
    Eur J Cancer; 2015 Jan; 51(2):202-9. PubMed ID: 25499439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining disease status in gastroenteropancreatic neuroendocrine tumors: Choi-criteria or RECIST?
    van Treijen MJC; Schoevers JMH; Heeres BC; van der Zee D; Maas M; Valk GD; Tesselaar MET
    Abdom Radiol (NY); 2022 Mar; 47(3):1071-1081. PubMed ID: 34989825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor response and clinical outcome in metastatic gastrointestinal stromal tumors under sunitinib therapy: comparison of RECIST, Choi and volumetric criteria.
    Schramm N; Englhart E; Schlemmer M; Hittinger M; Übleis C; Becker CR; Reiser MF; Berger F
    Eur J Radiol; 2013 Jun; 82(6):951-8. PubMed ID: 23518148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.